Published in Health and Medicine Week, August 7th, 2006
"We conducted a phase II trial of GEM with S-1, oral fluorouracil (5-FU) prodrug tegafur combined with two modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate, to evaluate the activity and toxicity of such a combination in metastatic pancreatic cancer (MPC) patients. Patients who had pathologically proven pancreatic cancer with metastatic lesions were eligible candidates for entry into the study," scientists writing in the British Journal of Cancer reported.
"S-1 was given orally (30 mg/m2) b.i.d. for 14...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week